Exchange-Traded Funds (ETFs)

PBE - PowerShares Dynamic Biotechnology & Genome Portfolio

Quantitative - Dynamic Industry

Product Details

The PowerShares Dynamic Biotechnology & Genome Portfolio (Fund) is based on the Dynamic Biotech & Genome IntellidexSM Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances biotechnology and genetic engineering and reseach. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

as of 03/31/2014 03/31/2014

Performance


   
as of 03/31/2014 03/31/2014
  YTD 1 Year 3 Year 5 Year 10 Year Fund Inception
Index History (%)
Dynamic Biotech & Genome Intellidex Index 12.72 59.85 24.98 28.04 N/A 13.24
S&P Biotech Index -0.11 38.85 40.78 26.73 14.60 16.66
S&P 500 Index 1.81 21.86 14.66 21.16 7.42 7.44
Fund History (%)
Fund NAV 12.77 59.02 24.17 27.03 N/A 12.67
After Tax Held 12.77 59.02 24.17 27.01 N/A 12.66
After Tax Sold 7.23 33.41 19.28 22.49 N/A 10.53
Fund Market Price 12.77 58.90 24.19 27.09 N/A 12.66

Monthly Standardized Report

Market returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times. Performance data quoted represents past performance, which is not a guarantee of future results. Investment returns and principal value will fluctuate, and shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than performance data quoted. After-tax returns reflect the highest federal income tax rate but exclude state and local taxes. Fund performance reflects fee waivers, absent which, performance data quoted would have been lower. After Tax Held and After Tax Sold are based on NAV.


as of 03/31/2014

Growth of $10,000

Data beginning Fund inception and ending 03/31/2014.

An investor cannot invest directly in an index. The results assume that no cash was added to or assets withdrawn from the Index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.

as of 04/17/2014

Subindustry Allocations

as of 04/17/2014

Market Cap & Style Allocations

Large-Cap Growth 24.29%
Large-Cap Blend 5.35%
Mid-Cap Growth 19.76%
Mid-Cap Value 2.97%
Mid-Cap Blend 7.97%
Small-Cap Growth 31.47%
Small-Cap Blend 8.20%

as of 04/17/2014 Top Holdings | View All

Fund Holdings subject to change

Ticker Company % of Fund
SIAL Sigma-Aldrich Corp 5.72
AMGN Amgen Inc 5.35
REGN Regeneron Pharmaceuticals Inc 5.13
BIIB Biogen Idec Inc 4.90
ALXN Alexion Pharmaceuticals Inc 4.87
GILD Gilead Sciences Inc 4.86
ILMN Illumina Inc 4.54
PCYC Pharmacyclics Inc 3.72
MYGN Myriad Genetics Inc 3.29
EBS Emergent Biosolutions Inc 3.22

Distributions | View All | Distribution Information

Ex-Date Record Date Pay Date $/
Share
Ordinary Income Short Term Gains Long Term Gains Return of Capital
09/20/2013 09/24/2013 09/30/2013 0.00000 0.00000 - - -
06/21/2013 06/25/2013 06/28/2013 0.00000 0.00000 - - -
03/15/2013 03/19/2013 03/28/2013 0.00000 0.00000 - - -
12/21/2012 12/26/2012 12/31/2012 0.00000 0.00000 - - -
09/21/2012 09/25/2012 09/28/2012 0.00000 0.00000 - - -
06/15/2012 06/19/2012 06/29/2012 0.00000 0.00000 - - -
03/16/2012 03/20/2012 03/30/2012 0.00000 0.00000 - - -
12/18/2009 12/22/2009 12/31/2009 0.07553 0.07553 - - -

Frequency Distribution of Discounts & Premiums

    Bid/Ask MidPoint Above NAV Bid/Ask Midpoint Below NAV
Quarter
Ending
Days 0.50-
0.99%
1.00-
1.99%
>2.00% 0.50-
0.99%
1.00-
1.99%
>2.00%
03/31/2014 61 0 0 0 0 0 1
12/31/2013 64 0 0 0 0 0 0
09/30/2013 64 0 0 0 0 0 0
06/30/2013 64 0 0 0 0 0 0
Year Ended 2013 252 0 0 0 1 0 0

Fund Inception: 06/23/2005

Shareholders may pay more than net asset value when they buy Fund shares and receive less than net asset value when they sell those shares, because shares are bought and sold at current market prices. Performance data quoted represents past performance, which is not a guarantee of future results.


 Risk & Other Information

Typically, security classifications used in calculating allocation tables are as of the last trading day of the previous month.

There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The Fund’s return may not match the return of the Underlying Index.

The Fund is considered non-diversified and may be subject to greater risks than a diversified fund.

Equity risk is the risk that the value of equity securities, including common stocks, may fall due to both changes in general economic and political conditions that impact the market as a whole, as well as factors that directly relate to a specific company or its industry.

Investments focused in a particular industry or sector, such as the biotech and genome and pharmaceuticals industries are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments.

Securities lending involves a risk of loss because the borrower may fail to return the securities in a timely manner or at all. If a Fund is unable to recover the securities loaned, it may sell the collateral and purchase a replacement security in the market. Lending securities entails a risk of loss to the Funds if and to the extent that the market value of the loaned securities increases and the collateral is not increased accordingly.

Investing in securities of small and medium-sized companies may involve greater risk than is customarily associated with investing in large companies.

The S&P Composite 1500® Biotech (S&P Biotech) Index consists of all biotechnology stocks included in the S&P Composite 1500® Index. The S&P 500® Index is an unmanaged index considered representative of the U.S. stock market.

The Global Industry Classification Standard was developed by and is the exclusive property and a service mark of MSCI, Inc. and Standard & Poor's.

The Intellidex™ Indexes are trademarks of NYSE Euronext or its affiliates and are licensed for use by Invesco PowerShares Capital Management LLC in connection with the PowerShares Intellidex investment products. The products are not sponsored or endorsed by NYSE Arca, and NYSE Arca makes no warranty or representation as to the accuracy and/or completeness of the Indexes or results to be obtained by any person from use of the Indexes or the trading of the products.

Beta is a measure of risk representing how a security is expected to respond to general market movements. Smart Beta represents an alternative and selection index based methodology that seeks to outperform a benchmark or reduce portfolio risk, or both. Smart beta funds may underperform cap-weighted benchmarks and increase portfolio risk.

as of 04/21/2014
10:14 AM EST

PBE

  • Last Trade $39.32
  • Current IIV $39.12
  • Change $0.19
  • % Change 0.49%
as of 04/17/2014
  • NAV at market close $39.17
as of 04/17/2014

Yield

  • SEC 30 Day Yield -0.16%
  • 30-Day SEC Unsubsidized Yield
    as of 04/17/2014
    N/A
as of 04/17/2014

Closing

  • Closing Price $39.13
  • Bid/Ask Midpoint $39.17
  • Bid/Ask Prem/Disc -
  • Bid/Ask Prem/Disc -
as of 03/31/2014

Fund Characteristics

  • Price/Earnings Ratio1 48.09
  • Price/Book Ratio1 6.56
  • ROE2 9.836%
  • Avg Market Cap2 $19,901MM

1 Weighted Harmonic Average

2 Weighted Average

Fund Details

  • Fund Ticker PBE
  • CUSIP # 73935X856
  • ISIN US73935X8561
  • Intraday NAV PBEIV
  • Index Ticker DZO
  • Index Provider NYSE Arca
  • Management Fee 0.50%
  • Total Expense Ratio 0.63%
  • Marginable Yes
  • Short Selling Yes
  • Options No
  • Exchange NYSE Arca
  • Inception Date 06/23/2005
  • # of Holdings 30
    as of 04/17/2014
as of 04/21/2014

Quick Facts

  • Previous Close $39.13
  • Open $39.29
  • Today's High $39.46
  • Today's Low $39.04
  • Today's Volume 10,679
  • 52 Week High $46.98
  • 52 Week Low $27.53
  • Shares Outstanding 9.00MM
  • Market Value $352.5MM